Snyder LL, Esser JM, Pachuk CJ, et al. Vector design for liver-specific expression of multiple interfering rnas that target hepatitis B virus transcrips[J]. Antiviral Res,2008,80:36-44.
[2]
Zhu XJ, Zhang XX. Clinical significance of quantitative assay of hepatitis B surface antigen[J]．Chin J HepatoI, 2011,19(8):637-640.(In Chinese)
Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association．Guideline on prevention and treatment of chronic hepatitis[J]．Chin Med J, 2007, 120, 2159-2173．
[7]
Mao YM,Zeng MD. Adefovir dipivoxil-A Hew drug for hepatitis B[J]. Chin J HepatoI, 2004,12(1)161-63．(In Chinese)
Liu ZH, Jiang JN, Li HD,et al. Influences of nucleoside on HBV cccDNA, tDNA and serum HBsAg in chronic hepatitis B patients[J]. Chinese General Practice, 2012, 15(3B):865-867. .(In Chinese)
Shin SR, Koh KC, Gwak GY, et a1．A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B[J]．Gut Liver,2010,4：530-536．
[12]
Wiegand J, Wedemeyer H,Finger A,et a1．A decline in hepatitis B virus surface antigen(HBsAg)predicts clearance,but does not cotrelate with quantitative HBeAg or HBV DNA levels[J]．Antivir Ther,2008,13：547 554．
[13]
Huang Yy, Zhang Xm, Liu Jx, et al. The long term efficacy of prediction analysis with quantitative HBsAg in e antigen positive chronic hepatitis B administrated with INF-α2b[J].Shangdong Medical Journal, 2010, 50(32):8-10. .(In Chinese)
